Diagnosis of Peripheral Lung Nodules Clinical Trial
Official title:
TH-168: Needle Based Confocal Laser Endomicroscopy For The Diagnosis Of Peripheral Lung Nodules By Robotic Navigational Bronchoscopy
| Verified date | February 2023 |
| Source | Fox Chase Cancer Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Needle based confocal laser endomicroscopy (nCLE) employs a small fiber which can be passed through a biopsy needle to enable real time microscopic imaging of cells. With resolution of 3.5 microns it is possible to identify key features consistent with malignancy and pulmonary fibrosis. (Wijmans, et al., 2019). The effectiveness of nCLE with intravenous fluorescein has been demonstrated in central lung cancers using esophageal ultrasound guided needle placement (Wijmans, et al., 2019). In this study, the proposed nCLE lung cancer criteria had high accuracy for lung cancer detection and were consistently recognized by multiple raters. Probe based confocal microscopy (pCLE) has also been used in conjunction with a radial probe EBUS in evaluating solitary pulmonary nodules with a diagnostic accuracy of 79.2%. (Hassan, et al., 2017) Needle based confocal laser endomicroscopy (nCLE) has not previously been used in conjunction with robotic navigational bronchoscopy.
| Status | Active, not recruiting |
| Enrollment | 25 |
| Est. completion date | December 2023 |
| Est. primary completion date | September 20, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Men and women, regardless of race, ethnic group or sexual orientation are eligible for this study. - Patients undergoing robotic navigational bronchoscopy for evaluation of indeterminate lung nodules with largest dimension size of 8-30 mm - Age > 18 years. - Patients must have normal organ and marrow functions as defined below: Leukocytes > 3,000/mcL Absolute neutrophil count > 1,500/mcL Total bilirubin within normal institutional limits Hemoglobin =7.0 AST/ALT (SGOT/SGPT) < 2 times institutional normal limits Creatinine OR Creatinine Clearance within normal institutional limits OR > 60 Ml/min/1.73 m2 for patients with creatinine levels above institutional normal - Ability to understand and willingness to sign a written informed consent and HIPAA consent document - WOCBP must agree not to get pregnant until after the day of the procedure Exclusion Criteria: - Patients with uncorrectable coagulopathy will be excluded. - Known allergy to fluorescein or other contrast media - Patients with hemodynamic instability will be excluded - Patients with refractory hypoxemia will be excluded - Patients with therapeutic anticoagulant that cannot be held for an appropriate interval prior to the procedure - Patients who are unable to tolerate general anesthesia according to the anesthesiologist - Patient requires chemotherapy - Pregnant or breast feeding. Refer to section 4.5 for further detail. - Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study - Pregnancy: Women of child-bearing potential (WOCBP) who are pregnant on the day of the procedure will be excluded from the study. |
| Country | Name | City | State |
|---|---|---|---|
| Netherlands | Amsterdam University Medical Center | Amsterdam | AZ |
| United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
| Lead Sponsor | Collaborator |
|---|---|
| Fox Chase Cancer Center | Johnson & Johnson, Mauna Kea Technologies |
United States, Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Ability to obtain good quality nCLE images of lung nodules | Good quality nCLE images of lung nodules/ surrounding tissue in =80% of patients provided the peripheral lung nodule | 1 year |